Literature DB >> 8492338

Clinical features and management of digitalis poisoning--rationale for immunotherapy.

P Taboulet1, F J Baud, C Bismuth.   

Abstract

The intensity of gastrointestinal and visual symptoms together with hyperkalemia and the characteristic ECG features make diagnosis of acute digitalis intoxication relatively easy. Death results mainly from ventricular fibrillation or from ventricular asystole or pump failure. Mesenteric infarct may also occur in elderly patients. Previous assessment of outcome has shown that mortality increases in patients exhibiting five prognostic factors: 1) advanced age; 2) heart disease; 3) male sex; 4) high-degree atrioventricular block; 5) hyperkalemia. Conventional treatment includes gastric lavage, activated charcoal and supportive care. First-line antiarrhythmic therapy is usually atropine, because of bradycardia-induced arrhythmia. Ventricular pacing is a toxicodynamic treatment that may be helpful in both bradycardia-induced arrhythmia and high-degree atrioventricular block. Pacing is difficult to handle and can result in serious adverse effects. Immunotherapy has two advantages. First, a strong toxicodynamic effect due to quick reversal of digitalis-induced dysrhythmias, hyperkalemia, and myocardial depression, by reactivation of membrane ATPases. Second, a toxicokinetic effect due to accelerated renal excretion of Fab-digitalis complexes. Since this therapy is well tolerated and efficient, we recommend early administration of Fab fragments as soon as poor prognostic factors are identified.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8492338     DOI: 10.3109/15563659309000392

Source DB:  PubMed          Journal:  J Toxicol Clin Toxicol        ISSN: 0731-3810


  10 in total

Review 1.  Pharmacological treatment of cardiac glycoside poisoning.

Authors:  Darren M Roberts; Gamini Gallapatthy; Asunga Dunuwille; Betty S Chan
Journal:  Br J Clin Pharmacol       Date:  2015-12-15       Impact factor: 4.335

Review 2.  Clinical applications of commonly used contemporary antidotes. A US perspective.

Authors:  C A Bowden; E P Krenzelok
Journal:  Drug Saf       Date:  1997-01       Impact factor: 5.606

Review 3.  A review of emergency cardiopulmonary bypass for severe poisoning by cardiotoxic drugs.

Authors:  Nicholas J Johnson; David F Gaieski; Steven R Allen; Jeanmarie Perrone; Francis DeRoos
Journal:  J Med Toxicol       Date:  2013-03

Review 4.  Advances in the management of digoxin toxicity in the older patient.

Authors:  S W Borron; C Bismuth; J Muszynski
Journal:  Drugs Aging       Date:  1997-01       Impact factor: 3.923

5.  Assessment of digoxin antibody use in patients with elevated serum digoxin following chronic or acute exposure.

Authors:  Frédéric Lapostolle; Stephen W Borron; Carine Verdier; Fabrice Arnaud; James Couvreur; Bruno Mégarbane; Frédéric Baud; Frédéric Adnet
Journal:  Intensive Care Med       Date:  2008-04-04       Impact factor: 17.440

Review 6.  Antidotes for acute cardenolide (cardiac glycoside) poisoning.

Authors:  D M Roberts; N A Buckley
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

7.  Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis.

Authors:  Andrea Perne; Markus K Muellner; Magdalena Steinrueck; Nils Craig-Mueller; Julia Mayerhofer; Ilse Schwarzinger; Mathew Sloane; Iris Z Uras; Gregor Hoermann; Sebastian M B Nijman; Matthias Mayerhofer
Journal:  PLoS One       Date:  2009-12-16       Impact factor: 3.240

Review 8.  Acute plant poisoning and antitoxin antibodies.

Authors:  Michael Eddleston; Hans Persson
Journal:  J Toxicol Clin Toxicol       Date:  2003

9.  Digoxin intoxication: An old enemy in modern era.

Authors:  Bahadir Kirilmaz; Serkan Saygi; Hasan Gungor; Ugur Onsel Turk; Emin Alioğlu; Serdar Akyuz; Fatih Asgun; Istemihan Tengiz; Ertugrul Ercan
Journal:  J Geriatr Cardiol       Date:  2012-09       Impact factor: 3.327

Review 10.  Clinical review: aggressive management and extracorporeal support for drug-induced cardiotoxicity.

Authors:  Frédéric J Baud; Bruno Megarbane; Nicolas Deye; Pascal Leprince
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.